Axsome Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $8.07B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 2, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 10, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 4, 2026 | Before market open | $191.20M | $-1.26 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 23, 2026 | Before market open | $196.00M | $-0.56 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 3, 2025 | Before market open | $171.00M | $-0.94 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 4, 2025 | Before market open | $150.00M | $-0.97 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 5, 2025 | Before market open | $121.50M | $-1.22 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 18, 2025 | Before market open | $118.80M | $-1.54 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 12, 2024 | Before market open | $104.80M | $-1.34 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 5, 2024 | Before market open | $87.20M | $-1.67 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 6, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 20, 2024 | Before market open | – | – | – |
Press releases
Announcements Axsome Therapeutics filed with the SEC
Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · Other events · EX-99.1 to Form 8-K
August 10, 2026 2Q 2026 Financial Results
Results of operations · Other events · EX-99.2 to Form 8-K
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
Other events · EX-99.1 to Form 8-K
Axsome Therapeutics Announces Settlement Resolving All SUNOSI ® (solriamfetol) Patent Litigation
Other events · EX-99.1 to Form 8-K
Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Results of operations · Other events · EX-99.1 to Form 8-K
May 4, 2026 1Q 2026 Financial Results
Results of operations · Other events · EX-99.2 to Form 8-K
Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Axsome Therapeutics Settles SUNOSI ® (solriamfetol) Patent Litigation with
Other events · EX-99.1 to Form 8-K
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue
Results of operations · Other events · EX-99.1 to Form 8-K
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-12 in Narcolepsy Supporting NDA Submission
Other events · EX-99.1 to Form 8-K
Axsome Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Results of operations · Other events · EX-99.1 to Form 8-K
November 3, 2025 3Q 2025 Corporate Presentation
Results of operations · Other events · EX-99.2 to Form 8-K
Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Results of operations · Other events · EX-99.1 to Form 8-K
August 4, 2025 2Q 2025 Corporate Presentation
Results of operations · Other events · EX-99.2 to Form 8-K
Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia
Other events · EX-99.1 to Form 8-K
Axsome Therapeutics Settles SUNOSI ® (solriamfetol) Patent Litigation with Hetero Labs Ltd.
Other events · EX-99.1 to Form 8-K
Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone
Material agreement · Agreement terminated · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Results of operations · Other events · EX-99.1 to Form 8-K
Corporate Presentation May 5, 2025
Results of operations · Other events · EX-99.2 to Form 8-K
Axsome Therapeutics Settles Sunosi ® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA
Other events · EX-99.1 to Form 8-K
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission
Other events · EX-99.1 to Form 8-K
Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Results of operations · Other events · EX-99.1 to Form 8-K
4Q and Full Year 2024 February 18, 2025 Corporate Presentation
Results of operations · Other events · EX-99.2 to Form 8-K
Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY ® (dextromethorphan HBr – bupropion HCl) Patent Litigation
Other events · EX-99.1 to Form 8-K
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue
Results of operations · Other events · EX-99.1 to Form 8-K
Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation
Other events · EX-99.1 to Form 8-K
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy
Other events · EX-99.1 to Form 8-K
Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Results of operations · Other events · EX-99.1 to Form 8-K
November 2024 3Q 2024 Corporate Presentation © Axsome Therapeutics, Inc.
Results of operations · Other events · EX-99.2 to Form 8-K
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
Other events · EX-99.1 to Form 8-K
Axsome Therapeutics Reaches Agreement to Dismiss Sunosi ® (Solriamfetol) Patent Litigation with Sandoz Inc.
Other events · EX-99.1 to Form 8-K
Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K